^
Association details:
| Biomarker: | EZH2 amplification |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
5580 / 4 - Circulating tumor DNA (ctDNA) identifies genomic alterations associated with resistance to Nivolumab in combination with other agents in metastatic castration-resistant prostate cancer from the CheckMate 9KD trial
Published date:
03/15/2023
Excerpt:
CheckMate 9KD (NCT03338790) was a nonrandomized, open-label, multicohort, phase 2 trial of nivolumab combined with rucaparib, docetaxel, or enzalutamide for mCRPC, which showed encouraging clinical activity for the nivolumab plus docetaxel combination....Amplifications in a number of genes detected in ctDNA including the androgen receptor (AR), PI3K/Akt pathway regulators (PIK3CA, PIK3CB, PREX2), and epigenetic regulators (DNMT3A, EZH2, KDM6A), were positively associated with poorer clinical outcomes (rPFS and/or OS) in the nivolumab + docetaxel arm.
Secondary therapy:
docetaxel
Trial ID:
